A common occurrence in the age of cancer immunotherapy, immune-related adverse events require multidisciplinary collaboration for investigation and optimal management. Drs. Cassandra and Leonard Calabrese discuss the ever-evolving field and the need for continuing education.
Primary immunodeficiency disorders (PID) have a growing spectrum of noninfectious complications. Vasculitis is one. Here’s what rheumatologists should take away from recent research.
Checkpoint inhibitor therapy for cancer holds great potential for durable response rates, but immune-related adverse events may be its Achilles’ heel.
A leading rheumatologist defines empathy and describes the process of losing it during medical training.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A leading rheumatologist discusses communication-based empathy techniques and why physicians should ‘fake it until you make it.’
The Director of the R.J. Fasenmyer Center for Clinical Immunology offers his thoughts on the teaching and learning of empathy.
After two decades of using biologics for IMIDs, we now have an armamentarium, including five drugs and a number of biosimilars, that continues to grow at a record pace.
By now most rheumatologists are aware that checkpoint inhibitors are capable of unleashing a wide array of autoimmune and autoinflammatory adverse events within virtually every organ system. These complications have posed new challenges to all practitioners.
No need to fear the vasculitides with this online, on-demand, complimentary CME.
Whether you plan to complete the entire series or prefer to pick a handful of individual webcasts most relevant to your practice, don’t miss this complimentary educational opportunity.